# Beacon Biosignals

> Beacon Biosignals is a Boston-based neurotechnology company that pairs FDA-cleared wearable EEG hardware with AI to turn brain electrical activity - especially during sleep - into scalable, at-home neurodiagnostics. Its platform powers drug development, clinical trials, and precision medicine across neurology, psychiatry, and sleep medicine.

- **Founded:** 2019
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Jacob Donoghue (Co-Founder & CEO (MD, PhD)), Jarrett Revels (Co-Founder & CTO), M. Brandon Westover (Co-Founder), Sydney Cash (Co-Founder)
- **Team size:** ~130 employees
- **Products:** Waveband (formerly Dreem 3S), Analytics Suites, Datastore, Beacon HQ, Onda (open source)
- **Notable:** FDA 510(k) clearance for the Dreem 3S (now Waveband) AI-assisted sleep monitoring device (Sept 2023)., First sleep wearable authorized by the FDA with a Predetermined Change Control Plan, allowing algorithm updates without a new submission (Dec 2024)., Raised an $86M Series B (Nov 2025), later upsized to over $97M (Apr 2026); cumulative funding over $132M.

## Products & services

- **Waveband (formerly Dreem 3S)** — FDA 510(k)-cleared wearable dry-EEG headband for at-home sleep monitoring; six electrodes plus accelerometer, with automated AASM sleep staging shown equivalent to in-lab polysomnography.
- **Analytics Suites** — AI/ML algorithms that score sleep architecture and surface neurobiomarkers from raw EEG for use in clinical trials and diagnostics.
- **Datastore** — Large-scale annotated EEG dataset and infrastructure used to train and validate brain-signal models.
- **Beacon HQ** — Software platform for managing EEG-based clinical studies and operations end to end.
- **Onda (open source)** — Open-source Julia tooling and Apache Arrow-based file format for high-throughput manipulation of structured, annotated time-series signal data.

## Achievements

- FDA 510(k) clearance for the Dreem 3S (now Waveband) AI-assisted sleep monitoring device (Sept 2023).
- First sleep wearable authorized by the FDA with a Predetermined Change Control Plan, allowing algorithm updates without a new submission (Dec 2024).
- Raised an $86M Series B (Nov 2025), later upsized to over $97M (Apr 2026); cumulative funding over $132M.
- Built one of the largest annotated EEG datasets and open-sourced core tooling (Onda.jl, OndaFormat).

## Latest updates

- **2026-04** — Upsized Series B to over $97M with new investors including Samsung Next, bringing cumulative funding past $132M.
- **2025-11** — Closed $86M Series B led by a healthcare and tech investor syndicate to scale at-home EEG and analytics.
- **2025-06** — Rebranded the Dreem 3S headband as 'Waveband' while retaining its FDA clearance.
- **2024-12** — FDA authorized the Dreem 3S's Predetermined Change Control Plan - a first for a sleep wearable.

## Links

- Website: https://beacon.bio
- LinkedIn: https://www.linkedin.com/company/beaconbiosignals
- Twitter/X: https://x.com/biosignals
- GitHub: https://github.com/beacon-biosignals

---

Profile page: https://yespress.io/beacon-biosignals
Published by YesPress — https://yespress.io
Last updated: 2026-06-07